IRCT138711271695N1CompletedPhase 3
Safety and usefulness of Enoxaparin versus unfractionated heparin in patients with ST elevation myocardial infarction
Tehran University of Medical Sciences and Health Services0 sites150 target enrollmentStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Enrollment
- 150
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 years to 75 years (—)
- Sex
- All
Inclusion Criteria
- •Inclusion Criteria: Age range 18 to 75 years old, onset of symptoms of acute myocardial infarction within 12 hrs before randomization, ST-segment elevation of 0.1 mV or more in two or more limbs leads or at least 0.2 mV in two or more precordial leads.
Exclusion Criteria
- •Contraindications to streptokinase, cardiogenic shock, receiving glycoprotein IIb/IIIa antagonists or oral anticoagulants within the prior days or therapeutic dose of heparin or low molecular-weight heparin within the previous hours, need for anticoagulant therapy and also any other disease that resulted in increasing risk
Investigators
Similar Trials
Recruiting
Phase 3
Enoxaparin in Treatment of Vascular Intra-Uterine Growth RetardatioIntra-uterine growth retardation.IRCT20180819040830N4Tehran University of Medical Sciences126
Completed
Phase 4
Enoxaparin Versus Unfractionated Heparin in Subjects Who Present to the Emergency Department With Acute Coronary Syndrome (RESCUE)Acute Coronary SyndromeNCT00077818Sanofi
Recruiting
Phase 3
Prophylactic vs. therapeutic enoxaparin in severe COVID-19IRCT20220412054515N1Tehran University of Medical Sciences220
Completed
Phase 3
Prevention of DVT in ACIRCT20190325043107N7Tabriz University of Medical Sciences120
Recruiting
Phase 3
The effectiveness of enoxaparin in preventing deep vein thrombosisDeep vein thrombosis.Phlebitis and thrombophlebitis of other deep vessels of lower extremitiesI80.2IRCT20210602051484N1Zanjan University of Medical Sciences200